Previous 10 | Next 10 |
home / stock / drug / drug articles
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court The U.S. Court of Appeals for the Ninth Circuit ruled against the Drug Enforc...
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma In...
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts Jada Pinkett Smith has joined the growing numb...
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares NY Mets owner Steve Cohen has bought as many as 119,092,680 ordinary...
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy...
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Billionaire hedge fund and NY Mets own...
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next MAPS Public Benefit Corporation (MAPS PBC), the nonprofi...
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassificat...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE: CYBN) and UK-bas...
News, Short Squeeze, Breakout and More Instantly...
Bright Minds Biosciences Inc. Company Name:
DRUG Stock Symbol:
NASDAQ Market:
Bright Minds Biosciences Inc. Website:
Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...
Bright Minds Biosciences Inc. (DRUG) is expected to report for quarter end 2023-12-31